Education
About Us
Working with TipRanks
Follow Us
Alphamab Oncology (HK:9966)
:9966
RESEARCH TOOLSreports
9966 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$2.10 - HK$9.35
Previous CloseN/A
Volume1.49M
Average Volume (3M)4.38M
Market Cap
HK$7.04B
Enterprise ValueN/A
Total Cash (Recent Filing)HK$1.57B
Total Debt (Recent Filing)¥185.96M
Price to Earnings (P/E)39.2
Beta1.72
Next Earnings
Aug 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding965,141,800
10 Day Avg. Volume3,319,700
30 Day Avg. Volume4,375,164
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-129.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Alphamab Oncology News
PremiumCompany Announcements
Alphamab Oncology Secures Shareholder Approval for Key Resolutions at AGMPremiumCompany Announcements
Alphamab Oncology Completes Share Placing by Controlling Shareholder
PremiumCompany Announcements
Alphamab Oncology Presents Promising JSKN003 Research at ASCO 2025
PremiumCompany Announcements
Alphamab Oncology’s Controlling Shareholder to Sell 1.51% Stake
PremiumCompany Announcements
Alphamab Oncology Grants Award Shares to Directors
PremiumCompany Announcements
Alphamab Oncology Schedules Annual General Meeting to Discuss Key Resolutions
PremiumCompany Announcements
Alphamab Oncology’s KN026 Trial Achieves Key Milestone
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.03%
Mutual Funds
― Other Institutional Investors
96.85% Public Companies and
Individual Investors
9966 FAQ
What was Alphamab Oncology’s price range in the past 12 months?
Alphamab Oncology lowest stock price was HK$2.10 and its highest was HK$9.35 in the past 12 months.
What is Alphamab Oncology’s market cap?
Alphamab Oncology’s market cap is HK$7.04B.
When is Alphamab Oncology’s upcoming earnings report date?
Alphamab Oncology’s upcoming earnings report date is Aug 28, 2025 which is in 69 days.
How were Alphamab Oncology’s earnings last quarter?
Alphamab Oncology released its earnings results on Mar 25, 2025. The company reported HK$0.238 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.238.
Is Alphamab Oncology overvalued?
According to Wall Street analysts Alphamab Oncology’s price is currently Overvalued.
Does Alphamab Oncology pay dividends?
Alphamab Oncology does not currently pay dividends.
What is Alphamab Oncology’s EPS estimate?
Alphamab Oncology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alphamab Oncology have?
Alphamab Oncology has 965,141,800 shares outstanding.
What happened to Alphamab Oncology’s price movement after its last earnings report?
Alphamab Oncology reported an EPS of HK$0.238 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.096%.
Which hedge fund is a major shareholder of Alphamab Oncology?
Currently, no hedge funds are holding shares in HK:9966
Alphamab Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
185.99%
12-Months-Change
Fundamentals
Return on Equity
9.52%
Trailing 12-Months
Asset Growth
1.39%
Trailing 12-Months
Company Description
Alphamab Oncology
Alphamab Oncology (9966) is a China-based biopharmaceutical company specializing in the development and commercialization of innovative oncology therapies. The company focuses on the research and development of multispecific biologics and antibody drug conjugates (ADCs) for the treatment of various forms of cancer. Alphamab Oncology leverages its proprietary technology platforms to create a robust pipeline of drug candidates aimed at addressing unmet medical needs in the oncology sector.
Technical Analysis
CanSino Biologics, Inc. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Akeso, Inc.
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Wuxi Biologics (Cayman)
―